Endonovo Pending Agreement to Develop Telehealth Division
Los Angeles, CA, June 07, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB:ENDV), an industry leading medical technology company, is working with a prominent developer of telehealth (telemedicine) platforms to establish a new telehealth division for Endonovo.
Related news for (ENDV)
- Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
- Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
- Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
- Endonovo’s SofPulse® Secures Taiwan FDA Approval
- Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution